Mirogabalin
Aliases: Tarlige, Ds-5565, Mirogabalin besylate, Mirogabalin monobenzenesulfonate
Categories
Summary
Mirogabalin is approved in Japan and several Asian countries for diabetic peripheral neuropathic pain and postherpetic neuralgia. It has higher binding affinity and slower dissociation from Ξ±2Ξ΄-1 subunits compared to pregabalin, potentially offering improved analgesic effects with fewer CNS side effects. Dose adjustments are necessary for renal impairment: 50% reduction for moderate impairment (CrCl 30-60 mL/min) and 75% reduction for severe impairment. Most common side effects include dizziness (8-16%), somnolence (6-29%), peripheral edema, headache, and weight gain. Not effective for fibromyalgia in clinical trials.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | - | - | - | 30+mg(notrecommended;supratherapeutic)+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 30-60 min | 1-2 hrs | 2-4 hrs | 3-6 hrs |
Tolerance
Build-up
develops over 1β4 weeks of regular use
Reset
days to weeks depending on duration of use
Effects
Positive
- Pain relief
- Physical euphoria
- Muscle relaxation
- Sleep enhancement
- Anxiolytic
- Muscle Relaxant
Negative
- Fatigue
- Sedation
- Sedative
- Dystaxia
Positive
- Anxiety suppression
- Reduced anxiety
- Cognitive euphoria
- Empathy enhancement
- Sociability enhancement
Negative
- Dizziness
- Cognitive dulling
- Motor control loss
- Amnesia
- Thought deceleration
Positive
- Increased music appreciation
- Increased libido
- Perception of bodily lightness
- Tactile enhancement
- Appetite enhancement
Negative
- Disinhibition
- Dehydration
- Double vision
- Decreased libido
- Dulled perception